Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-3.13%
$33.53
0% positive prob.
5-Day Prediction
-7.93%
$31.87
0% positive prob.
20-Day Prediction
-8.52%
$31.66
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q2 2026 | SELL | -3.13% | -7.93% | -8.52% | 100.0% | Pending |
| Q1 2026 | BUY | -0.06% | +18.88% | +21.51% | 100.0% | +15.59% |
| Q4 2025 | BUY | -0.12% | +21.70% | +23.84% | 100.0% | Pending |
| Q3 2025 | BUY | -0.33% | +21.24% | +27.79% | 100.0% | +23.55% |
SEC 8-K filings with transcript text
Aug 6, 2026 · 100% conf.
1D
-3.13%
$33.53
Act: +2.20%
5D
-7.93%
$31.87
20D
-8.52%
$31.66
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1786366268.ca53a40a
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
May 13, 2026 · 100% conf.
1D
-0.06%
$31.65
Act: +21.36%
5D
+18.88%
$37.64
Act: +15.59%
20D
+21.51%
$38.47
Act: -0.24%
2 vtvt-20260331xexx991pressr.htm
Document
Exhibit 99.1
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026
Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout
HIGH POINT, N.C., May 13, 2026 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the third quarter of 2026. vTv expects its current cash position to be sufficient to fund operations through the anticipated CATT1 topline data readout, positioning the Company to reach this key value inflection point with cash currently on hand.
“We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with type 1 diabetes,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. “Enrollment in our Phase 3 CATT1 trial continues to progress steadily, supported by expanded site activation and strong engagement from both investigators and patients. Importantly, with our recently strengthened balance sheet, we are well-capitalized to deliver on completion of enrollment and the anticipated topline data readout and drive long-term value for shareholders.”
Recent Company Highlights
•Phase 3 CATT1 Trial Progressing: Enrollment is ongoing in the Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in individuals with T1D. The Company expects to complete enrollment in the third quarter of 2026, supported by expanded site activation and increased investigator and patient engagement.
•License Amendment Adds Non-Dilutive Capital: In February 2026, the Company announced an amendment to its license agreement with Newsoara Biopharma, granting Newsoara global rights to the Company's highly selective PDE4 inhibitor, HPP737. Under the amended agreement, the Company received a $20.0 million upfront payment and is eligible to receive up to approximately $50.0 million in development milestones, up to $65.0 million in sales milestones, and tiered royalties on net sales. The transaction strengthens the Company's balance sheet and maintains strategic focus on advancing cadisegliatin.
First Quarter 2026 Financial Results
•Cash Position: Cash and cash equivalents as of March 31, 2026, were $98.1 million, compared to $88.9 million as of December 31, 2025. The increase reflects the $20.0 million upfront payment received under the recent amendment to the Newsoara license, partially offset by operating expenditures.
•Research & Development (R&D) Expenses: R&D expenses were $9.0 million and $2.8 million in each of the three months ended March 31, 2026, and 2025, respectively. The increase was primarily driven by continued investment in the Phase 3 CATT1 trial.
•General & Administrative (G&A) Expenses: G&A expenses were $4.6 million and $3.7 million for each of the three months ended March 31, 2026, and 2025, respectively. The increase reflects ongoing support for corporate operations and clinical development activities.
•Interest Income: Interest income for the three months ended March 31, 2026, and 2025, of $0.8 million and $0.3 million, respectively, is related to dividend income from our money market accounts.
•Net Income (Loss): Net income attributable to vTv shareholders for the three months ended March 31, 2026, was $24.1 million or $1.94 and $1.65 per basic and diluted share, respectively. Net loss attributable to vTv shareholders for the comparable period a year ago was $5.1 million or $0.77 per basic and diluted share.
Upcoming Events
•H.C. Wainwright 4th Annual BioConnect Investor Conference
Format: Fireside Chat & 1x1 Investor Meetings
Date: Tuesday, May 19, 2026
Time: 12:30 PM ET
Location: New York, NY
•Alliance Global Partners Healthcare Company Showcase
Format: Fireside Chat
Date: Wednesday, May 20, 2026
Time: 4:20 PM ET
Location: Virtual
vTv Therapeutics Inc.
Condensed Consolidated Balance Sheets
(in thousands)
March 31, 2026December 31, 2025
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$98,086 $88,932
Prepaid expenses521 743
Other current assets201 218
Total current assets98,808 89,893
Other assets5 6
Total assets$98,813 $89,899
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses$6,821 $6,557
Warrant liability, related party60 84
Total current liabilities6,881 6,641
Contract liabilities1,830 18,669
Warrant liability143 152
Total liabilities8,854 25
Mar 10, 2026 · 100% conf.
1D
-0.12%
$34.98
Act: +0.23%
5D
+21.70%
$42.62
20D
+23.84%
$43.37
vtvt-20260310FALSE0001641489Nasdaq00016414892026-03-102026-03-10
Date of Report (date of earliest event reported): March 10, 2026 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 110 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On March 10, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated March 10 2026, announcing financial results for the fiscal year ended December 31, 2025
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: March 10, 2026
Nov 6, 2025 · 100% conf.
1D
-0.33%
$25.23
Act: +0.75%
5D
+21.24%
$30.69
Act: +23.55%
20D
+27.79%
$32.34
Act: +8.06%
vtvt-20251106FALSE0001641489Nasdaq00016414892025-11-062025-11-06
Date of Report (date of earliest event reported): November 6, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On November 6, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated November 6 2025, announcing financial results for the fiscal quarter ended September 30, 2025
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: November 6, 2025
Aug 12, 2025
vtvt-20250812FALSE0001641489Nasdaq00016414892025-08-122025-08-12
Date of Report (date of earliest event reported): August 12, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On August 12, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated August 12 2025, announcing financial results for the fiscal quarter ended June 30, 2025
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: August 12, 2025
May 15, 2025
vtvt-20250515FALSE0001641489Nasdaq00016414892025-05-152025-05-15
Date of Report (date of earliest event reported): May 15, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On May 15, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated May 15, 2025, announcing financial results for the fiscal quarter ended March 31, 2025
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: May 15, 2025
Mar 20, 2025
vtvt-20250320FALSE0001641489Nasdaq00016414892025-03-202025-03-20
Date of Report (date of earliest event reported): March 20, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On March 20, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated March 20, 2025, announcing financial results for the fiscal year ended December 31, 2024
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: March 20, 2025
Nov 12, 2024
vtvt-20241112FALSE0001641489Nasdaq00016414892024-11-122024-11-12
Date of Report (date of earliest event reported): November 12, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On November 12, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated November 12, 2024, announcing financial results for the fiscal quarter ended September 30, 2024
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: November 12, 2024
Aug 8, 2024
vtvt-20240808FALSE0001641489Nasdaq00016414892024-08-082024-08-08
Date of Report (date of earliest event reported): August 8, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On August 8, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated August 8, 2024, announcing financial results for the fiscal quarter ended June 30, 2024
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: August 8, 2024
May 9, 2024
vtvt-20240509FALSE0001641489Nasdaq00016414892024-05-092024-05-09
Date of Report (date of earliest event reported): May 9, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On May 9, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated May 9, 2024, announcing financial results for the fiscal quarter ended March 31, 2024
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: May 9, 2024
Mar 13, 2024
vtvt-20240313FALSE0001641489Nasdaq00016414892024-03-132024-03-13
Date of Report (date of earliest event reported): March 13, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On March 13, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated March 13, 2024, announcing financial results for the fiscal year ended December 31, 2023
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: March 13, 2024
Feb 28, 2024
8-K
NASDAQ false 0001641489 0001641489 2024-02-28 2024-02-28
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024
vTv Therapeutics Inc. (Exact name of Registrant as specified in its charter)
Delaware
001-37524
47-3916571
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of Principal Executive Offices) (336) 641-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A common stock, par value $0.01 per share
Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement.
On February 28, 2024, vTv Therapeutics Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time, through TD Cowen, as sales agent, shares of the Company’s Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $50.0 million (the “ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will the Company sell securities registered on the registration statement relating to the ATM Offering with a value exceeding more than one-third of its public float in any 12-month period so long as its public float remains below $75.0 million. The Company is not obligated to sell any shares under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, TD Cowen will use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of the Nasdaq Stock Market, to sell shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. Under the Sales Agreement, TD Cowen may sell shares by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”). The Company will pay TD Cowen a commission equal to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements up to $75,000 and provide TD Cowen with customary indemnification and contribution rights. The Sales Agreement may be terminated by TD Cowen or the Company upon notice to the other party as provided in the Sales Agreement, or by TD Cowen at any time subject to certain conditions. The issuance and sale, if any, of the Shares by the Company under the Agreement will be made pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-254445) (the “Registration Statement”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 18, 2021, amended on April 9, 2021 and declared effective on April 20, 2021. The ATM Offering is described in the Company’s Prospectus dated April 20, 2021 (the “Base Prospectus), as supplemented by a Prospectus Supplement dated February 28, 2024 (the “Prospectus Supplement”). The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the opinion of Dechert LLP relating to the validity of the Shares to be issued pursuant to the Sales Agreement is filed herewith as Exhibit 5.1 hereto. The ATM Offering will only be
Aug 11, 2023
vtvt-20230811FALSE0001641489NASDAQ00016414892023-08-112023-08-11
Date of Report (date of earliest event reported): August 11, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On August 11, 2023, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated August 11, 2023, announcing financial results for the fiscal quarter ended June 30, 2023
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: August 11, 2023
May 11, 2023
vtvt-20230511FALSE0001641489NASDAQ00016414892023-05-112023-05-11
Date of Report (date of earliest event reported): May 11, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On May 11, 2023, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated May 11, 2023, announcing financial results for the fiscal quarter ended March 31, 2023
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: May 11, 2023
Mar 6, 2023
vtvt-20230306FALSE0001641489NASDAQ00016414892023-03-062023-03-06
Date of Report (date of earliest event reported): March 6, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On March 6, 2023, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated March 6, 2023, announcing financial results for the year ended December 31, 2022
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: March 6, 2023
Nov 10, 2022
vtvt-20221110FALSE0001641489NASDAQ00016414892022-11-102022-11-10
Date of Report (date of earliest event reported): November 10, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On November 10, 2022, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended September 30, 2022. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated November 10, 2022, announcing financial results for the fiscal quarter ended September 30, 2022
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: November 10, 2022
Aug 15, 2022
vtvt-20220815FALSE0001641489NASDAQ00016414892022-08-152022-08-15
Date of Report (date of earliest event reported): August 15, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37524 47-3916571
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)
3980 Premier Drive, Suite 310 High Point, NC 27265 (Address of principal executive offices) (336) 841-0300 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.01 per shareVTVTNASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition On August 15, 2022, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2022. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release dated August 15, 2022, announcing financial results for the fiscal quarter ended June 30, 2022
104Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:/s/ Paul J. Sekhri Name:Paul J. Sekhri Title:President and Chief Executive Officer
Dated: August 15, 2022
May 12, 2022
vtvt-8k_20220512.htm
false 0001641489
0001641489
2022-05-12 2022-05-12
Date of Report (date of earliest event reported): May 12, 2022
vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
001-37524
(Commission File No.)
47-3916571 (IRS Employer Identification No.)
3980 Premier Drive, Suite 310
High Point, NC 27265
(Address of principal executive offices)
(336) 841-0300
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a‑12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A common stock, par value $0.01 per share
NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 12, 2022, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated May 12, 2022, announcing financial results for the fiscal quarter ended March 31, 2022
104
Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:
/s/ Richard S. Nelson
Name:
Richard S. Nelson
Title:
Interim Chief Executive Officer
Dated: May 12, 2022
Mar 29, 2022
vtvt-8k_20220329.htm
false 0001641489
0001641489
2022-03-29 2022-03-29
Date of Report (date of earliest event reported): March 29, 2022
vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
001-37524
(Commission File No.)
47-3916571 (IRS Employer Identification No.)
3980 Premier Drive, Suite 310
High Point, NC 27265
(Address of principal executive offices)
(336) 841-0300
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a‑12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A common stock, par value $0.01 per share
NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On March 29, 2022, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2021. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated March 29, 2022, announcing financial results for the year ended December 31, 2021
104
Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:
/s/ Richard S. Nelson
Name:
Richard S. Nelson
Title:
Acting Chief Executive Officer
Dated: March 29, 2022
Nov 9, 2021
vtvt-8k_20211109.htm
false 0001641489
0001641489
2021-11-09 2021-11-09
Date of Report (date of earliest event reported): November 9, 2021
vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
001-37524
(Commission File No.)
47-3916571 (IRS Employer Identification No.)
3980 Premier Drive, Suite 310
High Point, NC 27265
(Address of principal executive offices)
(336) 841-0300
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a‑12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A common stock, par value $0.01 per share
NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 9, 2021, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended September 30, 2021. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated November 9, 2021, announcing financial results for the fiscal quarter ended September 30, 2021
104
Cover Page Interactive Data File (embedded within Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
By:
/s/ Rudy C. Howard
Name:
Rudy C. Howard
Title:
Chief Financial Officer
Dated: November 9, 2021
This page provides vTv Therapeutics Inc. (VTVT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on VTVT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.